Alnylam Pharmaceuticals stock trades at 147.70 euros late Friday
Published on 10/30/2026 at 21:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAlnylam At A Glance
- Alnylam develops and commercializes therapeutics based on RNA interference.
- The company is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals stock traded at 147.70 euros on Lang & Schwarz at 8:49 p.m. Berlin time on Friday, October 30, 2026.
Late Session Quote
The quote gives investors a late-session reference for the US biotechnology company after the regular trading day. No current Xetra closing comparison is included with this report.
RNAi Business Focus
Alnylam Pharmaceuticals develops and commercializes therapeutics based on ribonucleic acid interference, according to its company profile at Barron's. Its platform is aimed at medicines for serious diseases, making pipeline progress and commercial execution central factors for investors.
Following The Company
Investors can follow the real-time quote of Alnylam Pharmaceuticals stock for subsequent market updates.
The S&P 500 provides the relevant US market backdrop for investors.
More news and analyses on Alnylam Pharmaceuticals stock are available on the company topic page.
Alnylam Pharmaceuticals
- Company: Alnylam Pharmaceuticals
- ISIN: US02043Q1076
- Lang & Schwarz quote: 147.70 euros
- Quote date and time: Friday, October 30, 2026, 8:49 p.m. Berlin time
